<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DYAZIDE- hydrochlorothiazide and triamterene capsule </strong><br>Cardinal Health<br></p></div>
<h1>DYAZIDE®<br>(hydrochlorothiazide/triamterene)<br>Capsules<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_075c2a65-7ebf-4626-af18-9f973a4482d7"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each capsule of DYAZIDE (hydrochlorothiazide and triamterene) for oral use, with opaque red cap and opaque white body, contains hydrochlorothiazide 25 mg and triamterene 37.5 mg, and is imprinted with the product name DYAZIDE and SB. Hydrochlorothiazide is a diuretic/antihypertensive agent and triamterene is an antikaliuretic agent.</p>
<p>Hydrochlorothiazide is slightly soluble in water. It is soluble in dilute <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, dilute aqueous sodium hydroxide, and dimethylformamide. It is sparingly soluble in methanol.</p>
<p>Hydrochlorothiazide is 6-chloro-3,4-dihydro-2<span class="Underline">H</span>-1, 2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide, and its structural formula is:</p>
<div class="Figure"><img alt="Hydrochlorothiazide Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7330f40d-b269-425b-a4e3-e7263a088fb7&amp;name=7330f40d-b269-425b-a4e3-e7263a088fb7-01.jpg"></div>
<p>At 50°C, triamterene is practically insoluble in water (less than 0.1%). It is soluble in formic acid, sparingly soluble in methoxyethanol, and very slightly soluble in alcohol.</p>
<p>Triamterene is 2, 4, 7-triamino-6-phenylpteridine and its structural formula is:</p>
<div class="Figure"><img alt="Triamterene Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7330f40d-b269-425b-a4e3-e7263a088fb7&amp;name=7330f40d-b269-425b-a4e3-e7263a088fb7-02.jpg"></div>
<p>Inactive ingredients consist of benzyl alcohol, cetylpyridinium chloride, D&amp;C Red No. 33, FD&amp;C Yellow No. 6, gelatin, glycine, lactose, magnesium stearate, microcrystalline cellulose, povidone, polysorbate 80, sodium starch glycolate, titanium dioxide, and trace amounts of other inactive ingredients.</p>
<p> Capsules of DYAZIDE meet Drug Release Test 3 as published in the current USP monograph for Triamterene and Hydrochlorothiazide Capsules. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_98bedeee-70ed-46fd-b785-4d34eae25dd2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"> DYAZIDE is a diuretic/antihypertensive drug product that combines natriuretic and antikaliuretic effects. Each component complements the action of the other. The hydrochlorothiazide component blocks the reabsorption of sodium and chloride ions, and thereby increases the quantity of sodium traversing the distal tubule and the volume of water excreted. A portion of the additional sodium presented to the distal tubule is exchanged there for potassium and hydrogen ions. With continued use of hydrochlorothiazide and depletion of sodium, compensatory mechanisms tend to increase this exchange and may produce excessive loss of potassium, hydrogen, and chloride ions. Hydrochlorothiazide also decreases the excretion of calcium and uric acid, may increase the excretion of iodide, and may reduce glomerular filtration rate. The exact mechanism of the antihypertensive effect of hydrochlorothiazide is not known.</p>
<p>The triamterene component of DYAZIDE exerts its <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> on the distal renal tubule to inhibit the reabsorption of sodium in exchange for potassium and hydrogen ions. Its natriuretic activity is limited by the amount of sodium reaching its site of action. Although it blocks the increase in this exchange that is stimulated by mineralocorticoids (chiefly aldosterone), it is not a competitive antagonist of aldosterone and its activity can be demonstrated in adrenalectomized rats and patients with Addison’s disease. As a result, the dose of triamterene required is not proportionally related to the level of mineralocorticoid activity, but is dictated by the response of the individual patients, and the kaliureticeffect of concomitantly administered drugs. By inhibiting the distal tubular exchange mechanism, triamterene maintains or increases the sodium excretion and reduces the excess loss of potassium, hydrogen and chloride ions induced by hydrochlorothiazide. As with hydrochlorothiazide, triamterene may reduce glomerular filtration and renal plasma flow. Via this mechanism it may reduce uric acid excretion although it has no tubular effect on uric acid reabsorption or secretion. Triamterene does not affect calcium excretion. No predictable antihypertensive effect has been demonstrated for triamterene.</p>
<p>Duration of diuretic activity and effective dosage range of the hydrochlorothiazide and triamterene components of DYAZIDE are similar. Onset of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> with DYAZIDE takes place within 1 hour, peaks at 2 to 3 hours and tapers off during the subsequent 7 to 9 hours.</p>
<p>DYAZIDE is well absorbed. </p>
<p>Upon administration of a single oral dose to fasted normal male volunteers, the following mean pharmacokinetic parameters were determined:</p>
<a name="id_f87a1037-380f-4cfd-b7f7-ded421c3fe01"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AUC</span><span class="Bold"><span class="Sub">(0-48)</span></span></p>
<p><span class="Bold">ng*hrs/mL </span></p>
<p><span class="Bold">(± SD)</span></p>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">C</span><span class="Bold"><span class="Sub">max</span></span> </p>
<p><span class="Bold">ng/mL</span></p>
<p><span class="Bold">(± SD)</span></p>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Median </span></p>
<p><span class="Bold">T</span><span class="Bold"><span class="Sub">max</span></span></p>
<p><span class="Bold">Hrs </span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Ae</span></p>
<p><span class="Bold">Mg</span></p>
<p><span class="Bold">(± SD)</span></p>
</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Triamterene</p></td>
<td align="center" valign="top"><p class="First">148.7 (87.9)</p></td>
<td align="center" valign="top"><p class="First">46.4 (29.4)</p></td>
<td align="center" valign="top"><p class="First">1.1</p></td>
<td align="right" valign="top"><p class="First">2.7 (1.4)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">hydroxytriamterene sulfate</p></td>
<td align="center" valign="top"><p class="First">1,865 (471)</p></td>
<td align="center" valign="top"><p class="First">720 (364)</p></td>
<td align="center" valign="top"><p class="First">1.3</p></td>
<td align="right" valign="top"><p class="First">19.7 (6.1)</p></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><p class="First">hydrochlorothiazide</p></td>
<td align="center" valign="top"><p class="First">834 (177)</p></td>
<td align="center" valign="top"><p class="First">135.1 (35.7)</p></td>
<td align="center" valign="top"><p class="First">2.0</p></td>
<td align="right" valign="top"><p class="First">14.3 (3.8)</p></td>
</tr>
</tbody>
</table>
<p>where AUC<span class="Sub">(0-48),</span> C<span class="Sub">max</span>, T<span class="Sub">max</span> and Ae represent area under the plasma concentration versus time plot, maximum plasma concentration, time to reach C<span class="Sub">max</span>, and amount excreted in urine over 48 hours.</p>
<p> A capsule of DYAZIDE is bioequivalent to a single-entity 25 mg hydrochlorothiazide tablet and 37.5 mg triamterene capsule used in the double-blind clinical trial below (see Clinical Trials).</p>
<p>In a limited study involving 12 subjects, coadministration of DYAZIDE with a high-fat meal resulted in: (1) an increase in the mean bioavailability of triamterene by about 67% (90% confidence interval = 0.99, 1.90), p-hydroxytriamterene sulfate by about 50% (90% confidence interval = 1.06, 1.77), hydrochlorothiazide by about 17% (90% confidence interval = 0.90, 1.34); (2) increases in the peak concentrations of triamterene and p-hydroxytriamterene; and (3) a delay of up to 2 hours in the absorption of the active constituents.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_348b85ce-1396-4d8e-83cf-e786906d5065"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">A placebo-controlled, double-blind trial was conducted to evaluate the efficacy of DYAZIDE. This trial demonstrated that DYAZIDE (25 mg hydrochlorothiazide/37.5 mg triamterene) was effective in controlling blood pressure while reducing the incidence of hydrochlorothiazide-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. This trial involved 636 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> controlled by hydrochlorothiazide 25 mg daily and who had <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 mEq/L) secondary to the hydrochlorothiazide. Patients were randomly assigned to 4 weeks’ treatment with once-daily regimens of 25 mg hydrochlorothiazide plus placebo, or 25 mg hydrochlorothiazide combined with one of the following doses of triamterene: 25 mg, 37.5 mg, 50 mg, or 75 mg.</p>
<p>Blood pressure and serum potassium were monitored at baseline and throughout the trial. All five treatment groups had similar mean blood pressure and serum potassium concentrations at baseline (mean systolic blood pressure range: 137±14 mmHg to 140±16 mmHg; mean diastolic blood pressure range: 86±9 mmHg to 88±8 mmHg; mean serum potassium range: 2.3 to 3.4 mEq/L with the majority of patients having values between 3.1 and 3.4 mEq/L).</p>
<p>While all triamterene regimens reversed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, at week 4 the 37.5 mg regimen proved optimal compared with the other tested regimens. On this regimen, 81% of the patients had a significant (p&lt;0.05) reversal of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> vs. 59% of patients on the placebo/hydrochlorothiazide regimen. The mean serum potassium concentration on 37.5 mg triamterene went from 3.2±0.2 mEq/L at baseline to 3.7±0.3 mEq/L at week 4, a significantly greater (p&lt;0.05) improvement than that achieved with placebo/hydrochlorothiazide (i.e., 3.2±0.2 mEq/L at baseline and 3.5±0.4 mEq/L at week 4). Also, 51% of patients in the 37.5 mg triamterene group had an increase in serum potassium of ≥0.5 mEq/L at week 4 vs. 33% in the placebo group. The 37.5 mg triamterene/25 mg hydrochlorothiazide regimen also maintained control of blood pressure; mean supine systolic blood pressure at week 4 was 138±21 mmHg while mean supine diastolic blood pressure was 87±13 mmHg.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5e52a52d-7894-4ca9-8f6d-1b7c46b3f877"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">This fixed combination drug is not indicated for the initial therapy of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> except in individuals in whom the development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> cannot be risked.</span></p>
<p>DYAZIDE is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in patients who develop <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> on hydrochlorothiazide alone.</p>
<p>DYAZIDE is also indicated for those patients who require a thiazide diuretic and in whom the development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> cannot be risked.</p>
<p>DYAZIDE may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since DYAZIDE may enhance the action of these agents, dosage adjustments may be necessary.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_042a23eb-0cf9-4a84-86aa-d3bd7ff16d8f"></a><a name="section-4.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First"> The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as they are in the absence of pregnancy. <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b820e86a-5a95-409e-80d2-ef9db1e4a9d1"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa97c08a-8242-4e2c-85ee-caf8be62c1c3"></a><a name="section-5.1"></a><p></p>
<h2>Antikaliuretic Therapy and Potassium Supplementation</h2>
<p class="First"> DYAZIDE should not be given to patients receiving other potassium-sparing agents such as spironolactone, amiloride, or other formulations containing triamterene. Concomitant potassium-containing salt substitutes should also not be used.</p>
<p>Potassium supplementation should not be used with DYAZIDE except in severe cases of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e8a7e0d-51c3-4372-a290-21eeb0370d85"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First"> DYAZIDE is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, acute and <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> or significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48012fb0-ee8e-43dd-8299-64063371c65d"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_499e7fa9-9f83-46ce-8f12-b162d5766a7e"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First"> DYAZIDE should not be used in patients with preexisting elevated serum potassium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_3541c69c-1a12-467a-8b75-01f49aae28f1"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="id_91585ff5-6732-442e-89d5-6ae579d21b9b"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing diuretic combinations, including DYAZIDE. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> is more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (even without evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>), and in the elderly or severely ill. Since uncorrected <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients first receiving DYAZIDE, when dosages are changed or with any illness that may influence renal function.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_587b712d-49c2-4824-b846-5b8d540aa087"></a><a name="section-6.1"></a><p></p>
<p class="First">If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is suspected (warning signs include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> of the extremities, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), an electrocardiogram (ECG) should be obtained. However, it is important to monitor serum potassium levels because <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may not be associated with ECG changes.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is present, DYAZIDE should be discontinued immediately and a thiazide alone should be substituted. If the serum potassium exceeds 6.5 mEq/liter more vigorous therapy is required. The clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> solution, and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. Persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may require dialysis.</p>
<p>The development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> associated with potassium-sparing diuretics is accentuated in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see CONTRAINDICATIONS section). Patients with mild renal functional impairment should not receive this drug without frequent and continuing monitoring of serum electrolytes. Cumulative drug effects may be observed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The renal clearances of hydrochlorothiazideand the pharmacologically active metabolite of triamterene, the sulfate ester of hydroxytriamterene, have been shown to be reduced and the plasma levels increased following administration of DYAZIDE to elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> has been reported in diabetic patients with the use of potassium-sparing agents even in the absence of apparent <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Accordingly, serum electrolytes must be frequently monitored if DYAZIDE is used in diabetic patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_922bec3c-a98e-4aef-98c3-290e32cbc2b2"></a><a name="section-6.2"></a><p></p>
<h2>Metabolic or <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">Respiratory Acidosis</span></h2>
<p class="First"> Potassium-sparing therapy should also be avoided in severely ill patients in whom respiratory or <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may occur. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> may be associated with rapid elevations in serum potassium levels. If DYAZIDE is employed, frequent evaluations of acid/base balance and serum electrolytes are necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_93cb9807-e13e-497f-a719-62ac2fa316ce"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_a7d18f3a-4189-4c1e-8449-f4756441789a"></a><a name="section-7.1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e3c1628-1101-4741-8534-9d07f55e1cd0"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First"> Caution should be exercised when administering DYAZIDE to patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, since thiazides may cause <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, and alter insulin requirements in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Also, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may become manifest during thiazide administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52f28808-ea90-4b52-b89f-38817a65661d"></a><a name="section-7.3"></a><p></p>
<h2>Impaired Hepatic Function</h2>
<p class="First"> Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> in patients with severe liver disease. Potassium depletion induced by the thiazide may be important in this connection. Administer DYAZIDE cautiously and be alert for such early signs of impending <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> as <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>; if <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> increases discontinue DYAZIDE for a few days. Attention must be given to other factors that may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>, such as blood in the gastrointestinal tract or preexisting potassium depletion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f67e33b6-7b9e-4375-903d-d9d423a48449"></a><a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> is uncommon with DYAZIDE; but, should it develop, corrective measures should be taken such as potassium supplementation or increased intake of potassium-rich foods. Institute such measures cautiously with frequent determinations of serum potassium levels, especially in patients receiving digitalis or with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. If serious <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium less than 3.0 mEq/L) is demonstrated by repeat serum potassium determinations, DYAZIDE should be discontinued and potassium chloride supplementation initiated. Less serious <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> should be evaluated with regard to other coexisting conditions and treated accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_561ea500-369b-4f09-87aa-615dfeb5e2ba"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalance</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span>, often encountered in such conditions as <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or cirrhosis of the liver, may also be aggravated by diuretics and should be considered during therapy with DYAZIDE when using high doses for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> or in patients on a salt-restricted diet. Serum determinations of electrolytes should be performed, and are particularly important if the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving fluids parenterally. Possible fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may be indicated by such warning signs as: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa7d9cad-f778-4089-92d8-9a2aed38d238"></a><a name="section-7.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">Hypochloremia</span></h2>
<p class="First"> Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed41d241-3869-4542-a895-35becda33825"></a><a name="section-7.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal Stones</span></h2>
<p class="First"> Triamterene has been found in <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> in association with the other usual calculus components. DYAZIDE should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_214aa6e1-1c80-4f7d-bcba-9e38823e0ed8"></a><a name="section-7.8"></a><p></p>
<h2>Laboratory Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ebccbcb6-2cca-404c-b85d-9a013e578457"></a><a name="section-7.8.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Serum Potassium</span></span></h3>
<p class="First">The normal adult range of serum potassium is 3.5 to 5.0 mEq per liter with 4.5 mEq often being used for a reference point. If <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> should develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods.</p>
<p>Institute such measures cautiously with frequent determinations of serum potassium levels. Potassium levels persistently above 6 mEq per liter require careful observation and treatment. Serum potassium levels do not necessarily indicate true body potassium concentration. A rise in plasma pH may cause a decrease in plasma potassium concentration and an increase in the intracellular potassium concentration. Discontinue corrective measures for <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> immediately if laboratory determinations reveal an abnormal elevation of serum potassium.</p>
<p>Discontinue DYAZIDE and substitute a thiazide diuretic alone until potassium levels return to normal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61f0b7da-02f0-42ac-bc4c-77528018c504"></a><a name="section-7.8.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Serum Creatinine and BUN</span></span></h3>
<p class="First"> DYAZIDE may produce an elevated blood urea nitrogen level, creatinine level or both. This apparently is secondary to a reversible reduction of glomerular filtration rate or a depletion of intravascular fluid volume (prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>) rather than renal toxicity; levels usually return to normal when DYAZIDE is discontinued. If <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> increases, discontinue DYAZIDE. Periodic BUN or serum creatinine determinations should be made, especially in elderly patients and in patients with suspected or confirmed <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18275c73-538f-400f-9134-ffe2b1f9fb14"></a><a name="section-7.8.3"></a><p></p>
<h3><span class="Italics"><span class="Bold">Serum PBI</span></span></h3>
<p class="First"> Thiazide may decrease serum PBI levels without sign of thyroid disturbance.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3dc45429-7e10-41b8-8b06-f332e2d6435d"></a><a name="section-7.8.4"></a><p></p>
<h3><span class="Italics"><span class="Bold">Parathyroid Function</span></span></h3>
<p class="First"> Thiazides should be discontinued before carrying out tests for parathyroid function. Calcium excretion is decreased by thiazides. Pathologic changes in the parathyroid glands with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. The common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> such as bone resorption and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> have not been seen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_2ac3e14d-de8b-4055-88b2-119b804df676"></a><a name="section-7.9"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33fdffea-a080-426e-90a6-1c12e7b9b3e6"></a><a name="section-7.9.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Angiotensin-converting Enzyme Inhibitors</span></span></h3>
<p class="First"> Potassium-sparing agents should be used with caution in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to an increased risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1bf700d3-8ff3-4918-bbda-d615ddbfeacf"></a><a name="section-7.9.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Oral Hypoglycemic Drugs</span></span></h3>
<p class="First"> Concurrent use with chlorpropamide may increase the risk of severe <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9cd9537-27f5-40b0-9deb-b084018f5d1c"></a><a name="section-7.9.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Nonsteroidal Anti-inflammatory Drugs</span></span></h3>
<p class="First"> A possible interaction resulting in <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported in a few patients on DYAZIDE when treated with indomethacin, a nonsteroidal anti-inflammatory agent. Caution is advised in administering nonsteroidal anti-inflammatory agents with DYAZIDE.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdedf717-6dfa-4dd4-8b91-c28260ff9cb8"></a><a name="section-7.9.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Lithium</span></span></h3>
<p class="First"> Lithium generally should not be given with diuretics because they reduce its renal clearance and increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Read circulars for lithium preparations before use of such concomitant therapy with DYAZIDE.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4cbeeb96-cc11-452c-9b45-e7a636ea9849"></a><a name="section-7.9.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Surgical Considerations</span></span></h3>
<p class="First"> Thiazides have been shown to decrease arterial responsiveness to norepinephrine (an effect attributed to loss of sodium). This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine (an effect attributed to potassium loss); consequently caution should be observed in patients undergoing surgery.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2eccc66-9c0b-4ce1-96fa-cb7710e8aa57"></a><a name="section-7.9.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Other Considerations</span></span></h3>
<p class="First"> Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, although the presence of triamterene minimizes the hypokalemic effect.</p>
<p>Thiazides may add to or potentiate the action of other antihypertensive drugs. See INDICATIONS AND USAGE for concomitant use with other antihypertensive drugs.</p>
<p>The effect of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary.</p>
<p> DYAZIDE may raise the level of blood uric acid; dosage adjustments of antigout medication may be necessary to control <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>.</p>
<p>The following agents given together with triamterene may promote serum potassium accumulation and possibly result in <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> because of the potassium-sparing nature of triamterene, especially in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium).</p>
<p>Exchange resins, such as sodium polystyrene sulfonate, whether administered orally or rectally, reduce serum potassium levels by sodium replacement of the potassium; <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> may occur in some patients because of the increased sodium intake.</p>
<p>Chronic or overuse of laxatives may reduce serum potassium levels by promoting excessive potassium loss from the intestinal tract; laxatives may interfere with the potassium-retaining effects of triamterene.</p>
<p>The effectiveness of methenamine may be decreased when used concurrently with hydrochlorothiazide because of alkalinization of the urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_f82de6e7-4e76-488a-be18-606853aab1c7"></a><a name="section-7.10"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First"> Triamterene and quinidine have similar fluorescence spectra; thus, DYAZIDE will interfere with the fluorescent measurement of quinidine.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a840f72a-3e9e-4f69-bfa7-db42d381db97"></a><a name="section-7.11"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3340132b-9edb-4c86-a4fe-3fdec2370455"></a><a name="section-7.11.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Carcinogenesis</span></span></h3>
<p class="First">Long-term studies have not been conducted with DYAZIDE (the triamterene/hydrochlorothiazide combination), or with triamterene alone.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04127e65-0315-4f56-9323-a46f91dcaf8d"></a><a name="section-7.11.1.1"></a><p></p>
<h4><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></h4>
<p class="First"> Two-year feeding studies in mice and rats, conducted under the auspices of the National Toxicology Program (NTP), treated mice and rats with doses of hydrochlorothiazide up to 600 and 100 mg/kg/day, respectively. On a body-weight basis, these doses are 600 times (in mice) and 100 times (in rats) the Maximum Recommended Human Dose (MRHD) for the hydrochlorothiazide component of DYAZIDE at 50 mg/day (or 1.0 mg/kg/day based on 50 kg individuals). On the basis of body-surface area, these doses are 56 times (in mice) and 21 times (in rats) the MRHD. These studies uncovered no evidence of carcinogenic potential of hydrochlorothiazide in rats or female mice, but there was equivocal evidence of hepatocarcinogenicity in male mice.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_1c8e35f8-03e4-481e-a240-6c5ca7d359be"></a><a name="section-7.11.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Mutagenesis</span></span></h3>
<p class="First">Studies of the mutagenic potential of DYAZIDE (the triamterene/hydrochlorothiazide combination), or of triamterene alone have not been performed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f02f733a-1415-43f6-8e44-1e641c96b22d"></a><a name="section-7.11.2.1"></a><p></p>
<h4><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></h4>
<p class="First"> Hydrochlorothiazide was not genotoxic in in vitro assays using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537 and TA 1538 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (the Ames test); in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations; or in in vivo assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the <span class="Italics">Drosophila</span> sex-linked recessive lethal trait gene. Positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) test, and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43 to 1300 mcg/mL. Positive test results were also obtained in the <span class="Italics">Aspergillus nidulans</span> nondisjunction assay, using an unspecified concentration of hydrochlorothiazide.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_23b34282-e18f-43b8-b54a-4c4b575bc8bc"></a><a name="section-7.11.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Impairment of Fertility</span></span></h3>
<p class="First">Studies of the effects of DYAZIDE (the triamterene/hydrochlorothiazide combination), or of triamterene alone on animal reproductive function have not been conducted.</p>
<p> </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_782daf02-734f-4187-8b6b-b5e28f1893c8"></a><a name="section-7.11.3.1"></a><p></p>
<h4><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></h4>
<p class="First"> Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg/day, respectively, prior to mating and throughout gestation. Corresponding multiples of the MRHD are 100 (mice) and 4 (rats) on the basis of body-weight and 9.4 (mice) and 0.8 (rats) on the basis of body-surface area.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_84401373-a552-46f7-b515-f41776e1e490"></a><a name="section-7.12"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"> </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce3f3167-88f8-497a-846a-a82a69cb564a"></a><a name="section-7.12.1"></a><p></p>
<h3><span class="Bold">Category C</span></h3>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_a2d3d484-5ee3-4fb5-9133-9deed2cb676b"></a><a name="section-7.12.1.1"></a><p></p>
<h4><span class="Bold"><span class="Italics">Teratogenic Effects</span></span></h4>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6796d509-647a-4d73-a573-25184fd720d2"></a><a name="section-7.12.1.1.1"></a><p></p>
<h5><span class="Bold"><span class="Italics">DYAZIDE</span></span></h5>
<p class="First">Animal reproduction studies to determine the potential for fetal harm by DYAZIDE have not been conducted. However, a One Generation Study in the rat approximated composition of DYAZIDE by using a 1:1 ratio of triamterene to hydrochlorothiazide (30:30 mg/kg/day); there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at those doses which were, on a body-weight basis, 15 and 30 times, respectively, the MRHD, and on the basis of body-surface area, 3.1 and 6.2 times, respectively, the MRHD.</p>
<p>The safe use of DYAZIDE in pregnancy has not been established since there are no adequate and well-controlled studies with DYAZIDE in pregnant women. DYAZIDE should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6e9b8ac-f2eb-4198-bcb7-8e5847e6524b"></a><a name="section-7.12.1.1.2"></a><p></p>
<h5><span class="Bold"><span class="Italics">Triamterene</span></span></h5>
<p class="First"> Reproduction studies have been performed in rats at doses as high as 20 times the MRHD on the basis of body-weight, and 6 times the human dose on the basis of body-surface area without evidence of harm to the fetus due to triamterene.</p>
<p>Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1bc886a5-7b87-4e28-9a5e-e4e6d800686c"></a><a name="section-7.12.1.1.3"></a><p></p>
<h5><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></h5>
<p class="First"> Hydrochlorothiazide was orally administered to pregnant mice and rats during respective periods of major organogenesis at doses up to 3,000 and 1,000 mg/kg/day, respectively. At these doses, which are multiples of the MRHD equal to 3,000 for mice and 1,000 for rats, based on body-weight, and equal to 282 for mice and 206 for rats, based on body-surface area, there was no evidence of harm to the fetus.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response,this drug should be used during pregnancy only if clearly needed.</p>
<p> </p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_b603650e-4528-4d62-89a7-4f6ffdb8a74b"></a><a name="section-7.12.1.2"></a><p></p>
<h4><span class="Bold"><span class="Italics">Nonteratogenic Effects</span></span></h4>
<p class="First"> Thiazides and triamterene have been shown to cross the placental barrier and appear in cord blood. The use of thiazides and triamterene in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possible other adverse reactions which have occurred in the adult.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_78898cd1-2762-4225-86b4-5c95141ce669"></a><a name="section-7.13"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"> Thiazides and triamterene in combination have not been studied in nursing mothers. Triamterene appears in animal milk; this may occur in humans. Thiazides are excreted in human breast milk. If use of the combination drug product is deemed essential, the patient should stop nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_b9768a93-665a-4aad-800e-66af10b38919"></a><a name="section-7.14"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"> Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_218e2937-5535-4260-9bf2-5bdd9c11f016"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse effects are listed in decreasing order of severity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d0ea32b-e9fb-4b3d-bc4e-c98d692ca818"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, subacute <span class="product-label-link" type="condition" conceptid="4324123" conceptname="Cutaneous lupus erythematosus">cutaneous lupus erythematosus</span>-like reactions, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9b2e090-ef13-41e2-b8c3-b85015c3f13d"></a><a name="section-8.2"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_83d34331-5eb7-4558-8ae6-aa799c9dca6d"></a><a name="section-8.3"></a><p></p>
<h2>Metabolic</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9293242-7bfd-4c97-8ffc-68e2ee74b4a2"></a><a name="section-8.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and/or liver enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13124c0e-c991-498f-a8b5-b7d6f2de32cd"></a><a name="section-8.5"></a><p></p>
<h2>Renal</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> (one case of <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span> has been reported), interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> composed primarily of triamterene, elevated BUN, and serum creatinine, abnormal urinary sediment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3bc070a-fbc0-4ef9-a363-ea3eecde16d7"></a><a name="section-8.6"></a><p></p>
<h2>Hematologic</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ca24bf8-d8e6-48c3-827f-b75514cbbe00"></a><a name="section-8.7"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbadd5e8-0e17-4a55-b7b1-0616af601d0a"></a><a name="section-8.8"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bc0a3d3-1202-4af1-8acf-d7b34c34bc9d"></a><a name="section-8.9"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>.</p>
<p>Thiazides alone have been shown to cause the following additional adverse reactions:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f8af863-2ba5-40c5-9759-22595519d996"></a><a name="section-8.10"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9e02209-99e2-4b4f-aa4b-f833d253abcb"></a><a name="section-8.11"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">Xanthopsia</span>, transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01383a37-e45f-4cc0-a441-ff7daeba807a"></a><a name="section-8.12"></a><p></p>
<h2>Respiratory</h2>
<p class="First"> Allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c6c45f0-e904-475e-a7d2-0611c1ad5702"></a><a name="section-8.13"></a><p></p>
<h2>Other</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4039691" conceptname="Necrotizing vasculitis">Necrotizing vasculitis</span>, exacerbation of lupus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcbdf72f-dd15-41d8-847c-bf7cd303933e"></a><a name="section-8.14"></a><p></p>
<h2>Hematologic</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bef86f62-970d-4930-bbc3-3f76be9deb82"></a><a name="section-8.15"></a><p></p>
<h2>Neonate and infancy</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and pancreatitis−rarely, in newborns whose mothers have received thiazides during pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_7ee1d8b3-bd30-41e5-b815-7479d7113926"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">The usual dose of DYAZIDE is one or two capsules given once daily, with appropriate monitoring of serum potassium and of the clinical effect (see WARNINGS, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>).</span></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_198d7741-d5ad-4927-b568-597c5c415008"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> is the major concern (see WARNINGS section). Symptoms reported include: <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed face</span>, and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> deep tendon reflexes. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, it may be treated with pressor agents such as levarterenol to maintain blood pressure. Carefully evaluate the electrolyte pattern and fluid balance. Induce immediate evacuation of the stomach through <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage. There is no specific antidote.</p>
<p>Reversible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> following ingestion of 50 tablets of a product containing a combination of 50 mg triamterene and 25 mg hydrochlorothiazide has been reported.</p>
<p>Although triamterene is largely protein-bound (approximately 67%), there may be some benefit to dialysis in cases of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8d8e5420-4220-4dba-b41a-8eb86f8113f1"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Capsules containing 25 mg hydrochlorothiazide and 37.5 mg triamterene, in bottles of 1,000 capsules; in Patient-Pak™ unit-of-use bottles of 100.</p>
<p>They are supplied as follows:</p>
<p>NDC 0007-3650-22–in Patient-Pak™ unit-of-use bottles of 100.</p>
<p>NDC 0007-3650-30–bottles of 1,000.</p>
<p>Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). Protect from light. Dispense in a tight, light-resistant container.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>DYAZIDE is a registered trademark of GlaxoSmithKline.</p>
<p>©2007, GlaxoSmithKline. All rights reserved.</p>
<p>June 2007 DYZ:72PI</p>
<p>Cardinal Health </p>
<p>Zanesville OH 43701 </p>
<p>I12600308</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b38e58ef-57a9-4700-ae02-69f1dd6e9a89"></a><a name="section-12"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First"><span class="Bold">NDC 0007-3650-22</span>   (GLAXOSMITHKLINE)</p>
<p><span class="Bold">DYAZIDE<span class="Sup">®</span></span></p>
<p><span class="Bold">(hydrochlorothiazide and triamterene) </span></p>
<p><span class="Bold">25 </span><span class="Bold">mg/37.5mg </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p>1<span class="Bold">00 Capsules</span></p>
<p>Each capsule contains: Hydrochlorothiazide 25mg and Triamterene 37.5 mg.</p>
<p>GlaxoSmithKline</p>
<p>WARNING: Keep out of reach of children.</p>
<p><img alt="Dyazide Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7330f40d-b269-425b-a4e3-e7263a088fb7&amp;name=7330f40d-b269-425b-a4e3-e7263a088fb7-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DYAZIDE 		
					</strong><br><span class="contentTableReg">hydrochlorothiazide and triamterene capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4510(NDC:0007-3650)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydrochlorothiazide</strong> (hydrochlorothiazide) </td>
<td class="formItem">hydrochlorothiazide</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>triamterene</strong> (triamterene) </td>
<td class="formItem">triamterene</td>
<td class="formItem">37.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYLPYRIDINIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DYAZIDE;SB</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4510-1</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016042</td>
<td class="formItem">03/30/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7330f40d-b269-425b-a4e3-e7263a088fb7</div>
<div>Set id: 7330f40d-b269-425b-a4e3-e7263a088fb7</div>
<div>Version: 1</div>
<div>Effective Time: 20110104</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
